Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS
· Delayed Price · Currency is USD
0.0938
+0.0013 (1.36%)
At close: Dec 5, 2025
Oncotelic Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
26
Market Cap
41.42M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 122.89M |
| Glass House Brands | 196.17M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 25.83M |
| Global Cord Blood | 196.10M |
| Zomedica | 29.45M |
Oncotelic Therapeutics News
- 1 day ago - Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine - GlobeNewsWire
- 3 days ago - Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing - GlobeNewsWire
- 4 days ago - Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs - GlobeNewsWire
- 11 days ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation - GlobeNewsWire
- 15 days ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation - GlobeNewsWire
- 5 weeks ago - NetworkNewsAudio Announces Audio Press Release (APR) on Transforming Once-Marginal Drugs into Category-Changing Assets - GlobeNewsWire
- 5 weeks ago - Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies - GlobeNewsWire
- 5 weeks ago - Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) - GlobeNewsWire